Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Colorcon
McKesson
Baxter
Mallinckrodt

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Litigation Details for Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2017)

See Plans and Pricing

« Back to Dashboard

Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2017)

Docket   Start Trial Date Filed 2017-11-01
Court District Court, N.D. Illinois Date Terminated 2018-12-17
Cause 35:271 Patent Infringement Assigned To Rebecca R. Pallmeyer
Jury Demand None Referred To
Parties FRESENIUS KABI USA, LLC; HOSPIRA, INC.
Patents 8,242,158; 8,338,470; 8,455,527; 8,648,106; 9,320,712; 9,616,049
Attorneys Bradford P. Lyerla; Chad J. Ray; Sara Tonnies Horton; Yusuf Esat
Firms BR>Trial Bar Status: Active; BR>Trial Bar Status: Not a Member
Link to Docket External link to docket
Small Molecule Drugs cited in Hospira, Inc. v. Fresenius Kabi USA, LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2017)

Date Filed Document No. Description Snippet Link To Document
2017-11-01 1 infringement of U.S. Patent No. 9,616,049 (the “’049 patent”) (Ex. A) (the “Patent-in-suit”). … COUNT I FOR INFRINGEMENT OF PATENT NO. 9,616,049 17. Paragraphs 1 through… THE PATENT-IN-SUIT 9. The ’049 patent, entitled “Dexmedetomidine…assignee and owner of the ’049 patent. 10. The Patent-in-suit is duly listed in the… 4. This action is based upon the Patent Laws of the United States, 35 U.S.C. § 1 et seq External link to document
2018-12-17 109 Order on Motion for Partial Summary Judgment obtained four patents covering a new product made from dexmedetomidine: U.S. Patent Nos. 8,242,158 (the “’158…’158 Patent”), 8,338,470 (the “’470 Patent”), 8,455,527 (the “’527 Patent”), and 8,648,106 (the “’106…product—U.S. Patent No. 9,616,049 (the “’049 Patent”)—and filed a second complaint of patent infringement…obtained a patent that disclosed and claimed the compound: U.S. Patent No. 4,910,214 (the “’214 Patent”), JTX…named co- inventors of the patents-in-suit. (See ’106 Patent, JTX 1; ’049 Patent, JTX 2.) Dr. Roychowdhury External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Express Scripts
Johnson and Johnson
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.